<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687050</url>
  </required_header>
  <id_info>
    <org_study_id>Goethe-Uni-FFM-328-07</org_study_id>
    <nct_id>NCT00687050</nct_id>
  </id_info>
  <brief_title>Peroral Supplemental Nutrition in End-stage Renal Disease With and Without HIV Comorbidity</brief_title>
  <official_title>MRT-based Pilot Study to Evaluate Peroral Supplemental Nutrition for Prevention of Cachexia in End-stage Renal Disease With and Without HIV Comorbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfrimmer Nutricia GmbH, Erlangen , Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End-stage renal disease is often accompanied by malnutrition due to less appetite, metabolic
      changes or both. Human immunodeficiency virus-infection may exacerbate the state of
      malnutrition. In a pilot study, we recruit both HIV invected and non-infected patients on
      hemodialysis. Non-HIV patients will be randomized to peroral supplemental nutrition or no
      peroral supplemental nutrition. All HIV patients will receive peroral supplemental nutrition.
      The nutritional state will be determined in magnet resonance tomography at the start and at
      the end of the study (muscle diameter of triceps m.) and with laboratory parameters (plasma
      albumin and others). The hypothesis is that supplemental peroral nutrition (a total 250 kcal
      per day) will stop loss of muscle mass in end-stage renal disease patients (compared to their
      counterparts without supplemental peroral nutrition) as well as in the high risk group of HIV
      patients. This pilot study may lead to larger randomized clinical trials and, may affect
      dietary recommendations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In end-stage renal disease (ESRD), cachexia is a common finding. Metabolic changes,
      malnutrition, or both appear to be the underlying problems. In fact, lean body mass per body
      weight better predicts prognosis than creatinin based models (NDT, 2004.19:1182). In
      addition, comorbidity such as HIV infection may exacerbate cachexia found in ESRD. Whether or
      not daily supplemental, high-caloric nutrition in ESRD corrects a catabolic state in ESRD is
      unclear.

      Hypothesis to be tested:

      Daily supplemental high-caloric nutrition beneficially affects cytokine stimulation (TNF
      alpha, IL 1beta, IL 6, CrP) and nutritional state (cross sectional area of triceps m. in
      mid-humerus position (MRT), plasma albumin) in in HIV-positive hemodialysis patients and in
      chronic hemodialysis patients compared to chronic hemodialysis patients without supplemental
      nutrition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cross sectional area of triceps m. in mid-humerus position (MRT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma albumin &lt; 3.6 mg/dl</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Chronic hemodialysis patients randomized to no peroral supplemental nutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic hemodialysis patients randomized to peroral supplemental nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>peroral high-caloric supplemental nutrition</intervention_name>
    <description>HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Renilon 7.5 by Pfrimmer Nutricia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>peroral supplemental nutrition</intervention_name>
    <description>Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Renilon 7.5 by Pfrimmer-Nutricia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients on hemodialysis for more than 1 year,

          -  Group 1: HIV infection

        Exclusion Criteria:

          -  patients on hemodialysis for less than 1 year,

          -  Group 2 and 3: HIV infection

          -  no pre-/post dialysis weight differences of &gt; 3 kg after long HD free interval over
             last 10 HD sessions.

          -  no current high-caloric nutrition supplements or planned high-caloric supplements for
             clinical reasons.

          -  pregnancy

          -  for women: no use of oral contraceptives or other at least equally effective
             contraception in women with childbearing potential

          -  known neoplastic disease other than skin tumors (except melanoma)

          -  mental disease or retardation with impaired judgement power
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital of the Goethe University Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Rainer U. Pliquett</name_title>
    <organization>Goethe University Frankfurt am Main</organization>
  </responsible_party>
  <keyword>end-stage renal disease</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

